Kornimate/medical-research-clean huggingface dataset:
embodied virtual reality therapy for functional neurological symptom/ conversion disorder

Conditions: Conversion Disorder; Psychogenic Movement Disorder; Functional Movement Disorder; Functional Neurological Disorder; Non-epileptic Seizures

Summary: the purpose of this study is to design and test the safety and feasibility of virtual reality technologies and experiences of egocentric avatar embodiment in the application of physical and cognitive behavior therapy in functional neurological symptom/conversion disorder. investigators hypothesize that patients will safely use and accept this modality of treatment and will show evidence of a decrease in symptom frequency.

this is a treatment development trial, participants randomly assigned to active treatment will be enrolled in embodied virtual reality therapy. the therapy will be based on principals of exposure and behavioral shaping therapies and mirror visual feedback therapy. the therapy will be delivered over 8 sessions and modified as indicated by clinical feedback. a fixed protocol will be developed with exact methods to be used to be determined. after a fixed protocol has been established, a treatment manual will be created to use in further controlled trials.

Eligibility criteria:
inclusion criteria: * adults 18-65 years, who are diagnosed with functional neurologic symptom or conversion disorder. if diagnosis of seizure type then video eeg with diagnosis confirmed by board-certified neurologist with subspecialty training in epilepsy and clinical neurophysiology using the criteria of the international classification of the epilepsies is required. if diagnosis of motor type, documented and clinically established levels of diagnostic certainty (williams,1995) confirmed by 2 neurologists is required. * participants must have at least one symptom per month in the month prior to enrollment * fluency in english spoken language exclusion criteria: * nonfluency or inability to communicate in english spoken language * inability to participate or attend biweekly 30 minute session over 14 weeks * frank psychosis * active self harm urges * serious medical illness * active substance or alcohol use or dependence that could interfere with participation * diagnoses of mental retardation, dementia or delirium * pregnant women

Keywords: psychogenic non-epileptic seizures functional neurological symptom disorder pnes pmd virtual reality 3d augmented reality mirror therapy
hilotherapy-study on prevention of oxaliplatin-induced peripheral neuropathy

Conditions: Quality of Life; Chemotherapy-induced Peripheral Neuropathy

Summary: effectiveness of hilotherapy for the prevention of oxaliplatin-induced peripheral neuropathy and pain in the treatment of gastrointestinal tumors: a randomized controlled trial.

this study investigates whether constant cooling of the hands and feet using hilotherm chemocare devices reduces the incidence of (severe) oxaliplatin-induced peripheral neuropathy and pain compared to standard care (i.e. no hand and foot cooling) in patients with gastrointestinal tumors.

Eligibility criteria:
most important eligibility criteria: inclusion criteria: * 18 years or older * gastro-intestinal tumor, treated in uz leuven (university hospitals of leuven) * starting oxaliplatin-based treatment exclusion criteria: * already grade 2 or higher peripheral neuropathy for a more detailed list, see protocol.
risk factors of conversion from local to general sedation in endovascular stroke therapy

Conditions: Acute Stroke

Summary: thrombectomy is now the standard of care of revascularization in acute ischaemic stroke. data tend to show that final neurologic outcome is superior if the thrombectomy procedure was performed under conscious sedation. the rothschild foundation is a high output centre with more than 400 thrombectomy procedures every year. we report a rate of 5% of these procedures requiring general anesthesia despite conscious sedation being the standard of care. this study aims to identify clinical factors associated with a risk of conversion of a conscious sedation to a general anesthesia.


Eligibility criteria:
inclusion criteria: * patients undergoing thrombectomy for ischemic stroke * age ≥ 18 years old exclusion criteria: * patient already under general anesthesia * general sedation required * haemorrhagic softening diagnosed before the beginning of procedure * patient refusal to participate in the study
efficacy and tolerability of bisacodyl sugar coated tablets, simeticone chewing tablets and their combination in constipation and bloatedness

Conditions: Constipation

Summary: pilot study to evaluate the efficacy and tolerability of the combined treatment of bisacodyl and simeticone compared with the efficacy and tolerability of the single products in patients suffering from constipation and bloatedness


Eligibility criteria:
inclusion criteria: * diagnosis of constipation, defined as acute and habitual constipation; concomitantly patient must have complaint of bloated feeling * patient was to be 18 years of age or older * females who were of child bearing potential must have a negative pre-study urine pregnancy test and must be using oral or barrier contraceptive methods throughout the study. if oral contraceptives were used, the patient must be using them for at least 3 months prior to enrolment into the study * patient must be willing to maintain a diary throughout the study * patient must be otherwise in good health * patient must sign an informed consent form which has been prepared in accordance with the declaration of helsinki exclusion criteria: * patient had drug-induced constipation resulting from drugs such as opioids, dopaminergics, antacids, anticholinergics or diuretics * patient had a history of organic diseases of the colon such as tumors, stricture, and acute or chronic inflammatory diseases, ileus, acute surgical abdominal conditions such as acute appendicitis, or organic diseases of the rectum and anus such as fissures, fistulas, perianal abscesses, and eczema of the perianal skin * patient exhibited evidence of active gastrointestinal disease * patient was diagnosed as having intestinal obstruction, had any undiagnosed abdominal symptoms, or was in severe dehydration * patient had a history of major gastrointestinal surgery * patient had a history of hypersensitivity to substances of the triarylmethane class * patient had a history of hypersensitivity to substances of the class of parahydroxybenzoic esters (para group allergy) * patient had a history of drug or alcohol abuse * patient had received bisacodyl for the treatment of another indication or in a previous study within the last 7 days before enrolment. * patient had ingested any drug in the past week before enrolment that in the opinion of the investigator would have an effect on gastrointestinal motility (e.g. anti-cholinergic medications, opioids, smooth muscle relaxants or antacids) * patient required the use of a drug, other than study drug, or dietary supplement to relieve the symptoms of constipation at any time during the baseline or treatment phases of this study * patient was currently taking any form of tetracycline antibiotics * patient was a nursing mother * patient had received any investigational drug within the previous 4 weeks prior to enrolment * patient had any condition that would interfere with the completion of this study, or that would decrease the likelihood of obtaining valid results
non-interventional study in patients with peripheral or central neuropathic pain treated with lyrica

Conditions: Neuralgia

Summary: the purpose of this study is to obtain more data about efficacy and safety of the study drug lyrica.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of peripheral or central neuropathic pain exclusion criteria: * none. patients recruited by physician decision. patient's personal data are not collected.
multimodal high-frequency ultrasound-based study of plaque psoriasis severity index

Conditions: Plaque Psoriasis

Summary: psoriasis (pso) is a common chronic relapsing inflammatory disease, induced by a combination of genetic and environmental effects, which seriously affects the quality of life of patients.psoriasis area and severity index（pasi score ） ，as the most common method used by clinicians to assess the severity of psoriasis and the effectiveness of treatment, has the disadvantage of being subjective and superficial.we are therefore committed to establishing an objective, real-time, repeatable, non-invasive, microscopic assessment using high-frequency ultrasound. this study will use high-frequency ultrasound to detect the patient's lesion site and the 2cm site next to the lesion once, and the study will continue to recruit for 6 months.

high-frequency ultrasound (hfus) with a center frequency of more than 10 mhz, and a resolution of 16-158 μm. the detailed detection items are epidermal thickness (unit mm), dermal thickness (unit mm), hypoechoic cord thickness between epidermis and dermis (unit mm), epidermal echo intensity, dermal echo intensity, clarity of the boundary between dermis and subcutaneous tissue detected by grayscale ultrasound; blood flow signal (pcs) detected by color doppler imaging and power doppler imaging. the 8 tests will be detected the skin lesions and 2cm beside skin lesions area.based on the correlation between the 8 indexes and local pasi scores, we will establish a model for the evaluation of psoriasis by multimodal high-frequency ultrasound.this study will use high-frequency ultrasound to detect the patient's lesion site and the 2cm site next to the lesion once, and the study will continue to recruit for 6 months

Eligibility criteria:
inclusion criteria: 1. patients who meet the medical criteria for plaque psoriasis 2. those who voluntarily participate in this study and sign the informed consent form exclusion criteria: 1. patients with other types of psoriasis 2. those with other active medical conditions that may affect assessment 3. during a severe uncontrollable acute or chronic local or systemic infection 4. those with severe mental illness, cognitive impairment, and incapacity for personal behavior that makes them unsuitable to participate in a clinical study 5. other reasons the investigator considers unsuitable for participation in this study
multimodal approach to improve the outcome of patients with a proximal femoral fracture

Conditions: Proximal Femoral Fracture

Summary: this study is designed to compare the outcome of patients with proximal femoral fractures with different perioperative regimes: a group with a multimodal intervention and a control group.

femoral neck fractures constitute both a social and economic challenge. the one year mortality of affected patients amounts to 33%, wherein cardio-vascular complications are the major contributor. it is an objective of the present study to investigate whether a multi-modal perioperative intervention can improve the outcome of these patients. we plan to carry out a prospective randomized controlled clinical study. patients with an age above 60 years and proximal femoral fractures (femoral neck fractures or pertrochanteric femoral fractures) are to be included. these are divided into two groups, k and m. general anaesthesia is applied to both groups. in group k a commonly used therapy will be applied whereas in group m an intesified perioperative care will be carried out. the objectives are to provide sufficient analgesia, normotonia and normothermia. hence, a femoral catheter is applied for pain therapy already preoperatively. moreover, the pulmonal situation is improved by means of oxygen as needed. the cardiovascular situation is evaluated and optimized by means of extended hemodynamic monitoring both pre- and postoperatively. if needed, the nutrition of the patients is supplemented with highly caloric drinks. a primary common endpoint is the appearance of postoperative complications. these include cardiovascular, cerebrovascular, pulmonal, renal and surgical complications. secondary endpoints are mortality, duration of the stay at the hospital and intensive care duration. it is the objective of the study to reduce the probability for at least one postoperative complication from 50% to 25% (α=0,05 and 1-β=0,80). to this end 132 patients would have to be included in the study. all participants are to be contacted by phone one year after the surgery and their health situation is to be determined.

Eligibility criteria:
inclusion criteria: * proximal femoral fracture (femoral neck fracture/ pertrochanteric femoral fracture) * age ≥ 60 years * written informed consent exclusion criteria: * pathological fracture * multiple trauma * fracture during a hospital stay due to a different disease

Keywords: proximal femoral fracture multimodal intervention goal directed therapy (gdt) hemodynamic intervention outcome
reversal of battle-related aging (robra) in a special operations forces cohort

Conditions: Post-Traumatic Stress Disorder; Traumatic Brain Injury

Summary: the purpose of this study is to examine measures of grimage clock in sof members undergoing treatment for ptsd/tbi using csb.

the primary objective of this study is to assess the impact of a combined protocol of subanesthetic ketamine infusions (ski) and bilateral cervical sympathetic blocks (csb) on aging, as measured by the grimage epigenetic clock. the secondary objective of this study is to assess the impact of this treatment paradigm on ptsd and mental health, as measured over a 6 month time period using the following questionnaires: post-traumatic stress disorder checklist (pcl-5), patient health questionnaire 9 (phq-9), depressive symptom index-suicidality subscale (dsi-ss), generalized anxiety disorder 7-item (gad-7), and neurobehavioral symptom inventory (nsi). the tertiary objectives of the study are to investigate if ptsd is associated with significantly reduced free testosterone levels and increased c-reactive protein (crp) levels.

Eligibility criteria:
inclusion criteria: * recruited from sof with an active duty history of at least 5 years. * subjects may be in active duty or retired, male and female, between the ages of 40 and 60 years old. * the participants must have a confirmed diagnosis of ptsd, identified by posttraumatic stress disorder checklist for dsm-5 (pcl-5) scores higher than 40. * the participants must have been on a stable pharmacological or psychotherapeutic therapy for at least three months (if applicable), and continue this treatment throughout the duration of the study. * they must be able and willing to consent for the study. individuals who are able to become pregnant must adhere to a medically accepted method of contraception (eg. hormonal birth control, barrier birth control, intrauterine device, abstinence). exclusion criteria: * existing horner syndrome; * allergy to local anesthetics or contrast; * previous history of stellate ganglion block with psychosis; * admission to in-patient psychiatric facility within last 3 months; * history of moderate of severe tbi; * currently pregnant or breastfeeding; * current substance use disorder, or test positive for 1 or more illegal or controlled drugs on the initial urine drug screen, such as cocaine, marijuana, amphetamines, opioids, benzodiazepines, amongst others; * previous behavioral health diagnoses (bipolar i, psychosis, etc); * currently undergoing exposure therapy.
clinical comparison of bulk-fill restorative and nano-fill resin composite

Conditions: Dental Caries

Summary: the aim of this study is to evaluate the clinical performance of a nano-fill and a bulk fill resin composite in class ii restorations.

in accordance with a split-mouth design, 50 patients will be received at least one pair of restorations, restored with a nanofill resin composite (filtek ultimate \[fu\]) and with a bulk fill resin composite (tetric evoceram bulk fill \[tb\]). each restorative resin will be used with its respective adhesive system according to the manufacturers' instructions. a total of 104 class ii restorations will be placed by two operators. the restorations will be blindly evaluated by two examiners at baseline and at 1-, 2-, 3-, 4-, 5-, 6-, 7- and 8- year using modified us public health service ryge criteria. the comparison of the two restorative materials for each category will be performed with the chi-square test (a=0.05). the baseline scores will be compared with those at the recall visits using the cochran q-test.

Eligibility criteria:
inclusion criteria: * a need for at least two but not more than four posterior tooth-colored restorations * the presence of teeth to be restored in occlusion * teeth that were symptomless and vital * a normal periodontal status * a good likelihood of recall availability. exclusion criteria: * partly erupted teeth * absence of adjacent and antagonist teeth * poor periodontal status * adverse medical history * potential behavioral problems
gemcitabine, infusional 5 fluorouracil and bevacizumab in patients with advanced pancreas cancer

Conditions: Pancreatic Cancer

Summary: this is a phase ii study of biweekly (every other week) bevacizumab followed by gemcitabine then infusional 5-fluorouracil in patients with stage iii or iv pancreatic cancer. patients' response will be evaluated every 8 weeks using usual ct scanning techniques. recist (response evaluation criteria in solid tumors) criteria will be applied to evaluate response. tumor marker levels (ca 19-9) will be assessed every 4 weeks, but will not be used to measure response.

rationale: research indicates that the vascular endothelial growth factor (vegf), or a substance made by cells that stimulates new blood vessel formation, plays an important role in the growth and metastasis of many cancers, including pancreatic carcinoma. both vegf and its receptors are overexpressed in pancreatic cancer. bevacizumab works by blocking vegf and the growth of cancer cells in the process. the current study combines bevacizumab with two commonly used pancreatic cancer drugs, gemcitabine and infusional 5-fu. previous studies indicate that bevacizumab combined with other anti-cancer drugs such as 5-fu improves patient survival. in addition, other research suggests that the drug administration schedule of the current study may improve patient outcomes compared to other types of administration and sequencing. purpose: the primary objective of this study is to assess the rate of progression free survival at 6 months in patients with advanced pancreatic cancer given gemcitabine, infusional 5-fu, and bevacizumab. secondary objectives of this study include measuring response rates, 6 month and 1-year survival rates, and median overall survival. treatment: study participants will be given bevacizumab, gemcitabine, and 5-fu. these drugs will be administered through intravenous infusions in that order every other week on days 1 and 15. treatments will be given in 28-day cycles. participants will therefore receive study drugs during weeks 1 and 3, and then receive no study drugs during weeks 2 and 4. imaging exams will be performed every 8 weeks to assess disease size. several other tests will be given throughout the study to closely monitor patients. tumor level markers will be assessed every 4 weeks, but will not be used to measure response. study treatments will be discontinued due to disease growth or severe adverse effects.

Eligibility criteria:
inclusion criteria: * males or females age \>=18 years. * established histological confirmation of adenocarcinoma of the pancreas. * stage iii and stage iv will be allowed. exclusion criteria: * no prior chemotherapy or radiotherapy allowed except for that given as part of an adjuvant regimen if \>4 weeks have elapsed since the end of therapy. any prior treatment with antibodies to vegf. * major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting the study. * pregnant or lactating women.

Keywords: advanced pancreatic cancer
neuroliten mvp system clinical observation study

Conditions: Epilepsy

Summary: this is an observational study for data collection from subjects diagnosed with epilepsy/intractable seizures. the neuroliten mvp system will not be used for patient management or treatment decisions.

neuroliten mvp system stores the data obtained from wearables, caregivers, and all audio/video recording of seizure activity that the caregiver captures associated with a seizure episode. the primary objective of this study is to obtain vital signs and neurological indicators via the neuroliten mvp system to correlate to the onset of seizures that are detected by the observations of family/caregivers. the secondary objective is to identify the vital signs and/or neurological indicators that are associated with seizure onset.

Eligibility criteria:
inclusion criteria: 1. an institutional review board (irb) approved informed consent is signed and dated before any study-related activities. 2. male and female subjects ages 18 to 75, inclusive. 3. documented history of at least two (2) seizures per week. seizures can be generalized and/or focal. 4. diagnosed with intractable or refractory epilepsy. 5. have a caregiver/family member who stays with the subject, has the ability to detect seizures, and is willing to provide the information needed for the study. 6. have implanted vagus nerve stimulation (vns). 7. have the ability to understand the requirements of the study and are willing to comply with all study requirements. 8. must have a working apple iphone. exclusion criteria: 1. women who are either pregnant or breastfeeding. 2. subjects unable/unwilling to wear the apple watch and eeg wearable for extended periods. 3. requires the use of a ventilator. 4. requires the use of supplemental oxygen. 5. uses a pacemaker or other electronic neurostimulator, except the vns. 6. any medical or surgical condition that in the opinion of the investigator may interfere with participation in the study.

Keywords: seizures
asthma, inflammation and g protein-coupled receptors (gpcr)

Conditions: Asthma; COPD

Summary: the g protein-coupled receptors (gpcrs) are a family of proteins expressed at the cell membrane. they are composed of 380 members involved in the important functions of the organism and are privileged therapeutic targets.their expression is highly modulated depending on the metabolic state of the cells, in particular in pathological situations.our study proposes to determine whether gpcr expression modulation could be used as a biomarker, either prognostic or diagnostic, of treatments.to do so , the investigators will determine the expression profile of the 380 human gpcrs in human blood cell samples in two chronic inflammatory pulmonary diseases : asthma and copd (chronic obstructive pulmonary disease ) . these have opposed inflammatory infiltrates : asthma is associated with eosinophil and th2 lymphocyte infiltration whereas copd shows neutrophils and macrophages within the airways with a th1 lymphocytic population. the gpcr signature (transcriptomic) will be determined on total white blood cells as well as on isolated mono- and poly-nuclear populations obtained from healthy subjects and patients selected at the asthma or copd consultation. the expression profiling analysis will reveal sub-groups of gpcrs whose expression is modified in disease. the specificity of the variation of expression of these biomarker sub-populations will be determined, by a study recruiting a hundred patients and controls per disease on this restraint number of genes. the outcomes of the project will lead to establish gpcr "identity cards" for these chronic inflammatory diseases, which might therefore be used as diagnostic or prognostic biomarkers to follow the evolution of a disease or the efficacy of a given treatment. in addition, detailed analysis of the identified gpcrs will lead to propose new therapeutic targets for inflammatory diseases. this study has therefore the objective of validating gpcrs as potential biomarkers for inflammatory diseases.

multicentre non-randomized

Eligibility criteria:
inclusion criteria: * asthma group * copd group * control group exclusion criteria: * patients with infection or inflammatory diseases

Keywords: gpcr expression transcriptomic white blood cells diagnostic control